which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have b ...

The new Alzheimer’s drug Kinsula is offering hope for patients by slowing down the progression of the disease. Neurologist Dr. Mauricio Concha administered the drug ...

If the European Medicines Agency takes an overly cautious approach to selecting specialists to advise on new medicines, ...

A chemist a UAlbany and his son are looking to make a major breakthrough in the world of Alzheimer's prevention. They believe ...

Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.

According to the FDA, the drug is approved for people with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and those with the mild dementia stage of Alzheimer’s ...

After a lull of nearly 2 decades, the Food and Drug Administration (FDA) has approved some ... a third of people living with dementia in the UK don’t get a diagnosis at all.

Leqembi, an Alzheimer's drug from Biogen and Eisai, faces hurdles with respect to reimbursement and diagnostic uncertainties, diagnostic test requirements and the need for regular brain scans, CNBC ...

The recent FDA approval of Eli Lilly’s new immunotherapy ... Dr Howard Fillit, co-founder and chief science officer of the Alzheimer’s Drug Discovery Foundation (ADDF) described the latest ...

AC Immune said its partner Life Molecular Imaging received fast-track designation from the U.S. Food and Drug Administration ... conditions: Alzheimer's disease, progressive supranuclear palsy ...